Boron neutron capture therapy for urological cancers.
BNCT
boron
neutron
urological cancers
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
25
11
2021
accepted:
21
02
2022
pubmed:
4
3
2022
medline:
8
7
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
Boron neutron capture therapy is based on a nuclear reaction between the nonradioactive isotope boron-10 and either low-energy thermal neutrons or high-energy epithermal neutrons, which generate high linear energy transfer α particles and a recoiled lithium nucleus (
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-616Informations de copyright
© 2022 The Japanese Urological Association.
Références
Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat. Res. 1999; 151: 1-18.
Suzuki M. Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era. Int. J. Clin. Oncol. 2020; 25: 43-50.
Nedunchezhian K, Aswath N, Thiruppathy M, Thirugnanamurthy S. Boron neutron capture therapy - a literature review. J. Clin. Diagn. Res. 2016; 10: https://doi.org/10.7860/JCDR/2016/19890.9024.
Hiratsuka J, Kamitani N, Tanaka R et al. Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget's disease with curative responses. Cancer Commun. 2018; 38: 38.
Mishima Y, Honda C, Ichihashi M et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet 1989; 2: 388-9.
Wittig A, Sauerwein WA, Coderre JA. Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat. Res. 2000; 153: 173-80.
Wongthai P, Hagiwara K, Miyoshi Y et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 2015; 106: 279-86.
Imahori Y, Ueda S, Ohmori Y et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J. Nucl. Med. 1998; 39: 325-33.
Barth RF, Zhang Z, Liu T. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun. 2018; 38: 36.
Hatanaka H. A revised boron-neutron capture therapy for malignant brain tumors. II. Interim clinical result with the patients excluding previous treatments. J. Neurol. 1975; 209: 81-94.
Soloway AH, Hatanaka H, Davis MA. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J. Med. Chem. 1967; 10: 714-7.
Iguchi Y, Michiue H, Kitamatsu M et al. Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. Biomaterials 2015; 56: 10-7.
Suzuki M, Kato I, Aihara T et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J. Radiat. Res. 2014; 55: 146-53.
Fuentes I, Garcia-Mendiola T, Sato S et al. Metallacarboranes on the road to anticancer therapies: cellular uptake, DNA interaction, and biological evaluation of cobaltabisdicarbollide [COSAN]−. Chemistry 2018; 24: 17239-54.
Dukenbayev K, Korolkov I, Tishkevich D et al. Fe3O4 Nanoparticles for complex targeted delivery and boron neutron capture therapy. Nanomaterials 2019; 9: 494.
Ali F, S Hosmane N, Zhu Y. Boron chemistry for medical applications. Molecules 2020; 25: 828.
Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: current status and future perspectives. Cancer Commun. 2020; 40: 406-21.
Asbury AK, Ojemann RG, Nielsen SL, Sweet WH. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J. Neuropathol. Exp. Neurol. 1972; 31: 278-303.
Farr LE, Sweet WH, Locksley HB, Robertson JS. Neutron capture therapy of gliomas using boron. Trans. Am. Neurol. Assoc. 1954; 13: 110-3.
Goodwin JT, Farr LE, Sweet WH, Robertson JS. Pathological study of eight patients with glioblastoma multiforme treated by neutron-capture therapy using boron 10. Cancer 1955; 8: 601-15.
Miyatake S-I, Kawabata S, Hiramatsu R et al. Boron neutron capture therapy for malignant brain tumors. Neurol. Med. Chir. 2016; 56: 361-71.
Chen Y-W, Lee Y-Y, Lin C-F et al. Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: evaluation of 34 cases in Taiwan. Biology (Basel) 2021; 10: 334.
Miyatake SI, Wanibuchi M, Hu N, Ono K. Boron neutron capture therapy for malignant brain tumors. J. Neurooncol. 2020; 149: 1-11.
Kawabata S, Suzuki M, Hirose K et al. Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study. Neurooncol. Adv. 2021; 3: vdab067.
Chadha M, Capala J, Coderre JA et al. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int. J. Radiat. Oncol. Biol. Phys. 1998; 40: 829-34.
Chanana AD, Capala J, Chadha M et al. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery 1999; 44: 1182-92.
Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J. Neurooncol. 2003; 62: 101-9.
Henriksson R, Capala J, Michanek A et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother. Oncol. 2008; 88: 183-91.
Joensuu H, Kankaanranta L, Seppälä T et al. Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J. Neurooncol. 2003; 62: 123-34.
Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl. Radiat. Isot. 2011; 69: 1823-5.
Kageji T, Nagahiro S, Matsuzaki K et al. Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 1446-55.
Kankaanranta L, Seppälä T, Koivunoro H et al. L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a phase I study. Int. J. Radiat. Oncol. Biol. Phys. 2011; 80: 369-76.
Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S. Boron neutron capture therapy for recurrent high-grade meningiomas. J. Neurosurg. 2013; 119: 837-44.
Kawabata S, Miyatake S-I, Kuroiwa T et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J. Radiat. Res. 2009; 50: 51-60.
Kawabata S, Miyatake S-I, Nonoguchi N et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl. Radiat. Isot. 2009; 67: S15-8.
Miyatake S-I, Kawabata S, Kajimoto Y et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J. Neurosurg. 2005; 103: 1000-9.
Miyatake S-I, Kawabata S, Yokoyama K et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J. Neurooncol. 2009; 91: 199-206.
Shiba H, Takeuchi K, Hiramatsu R et al. Boron neutron capture therapy combined with early successive bevacizumab treatments for recurrent malignant gliomas - a pilot study. Neurol. Med. Chir. 2018; 58: 487-94.
Sköld K, H-Stenstam B, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW. Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol. Scand. 2010; 122: 58-62.
Vos MJ, Turowski B, Zanella FE et al. Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61: 392-9.
Yamamoto T, Matsumura A, Nakai K et al. Current clinical results of the Tsukuba BNCT trial. Appl. Radiat. Isot. 2004; 61: 1089-93.
Yamamoto T, Nakai K, Kageji T et al. Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother. Oncol. 2009; 91: 80-4.
Kankaanranta L, Seppälä T, Koivunoro H et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int. J. Radiat. Oncol. Biol. Phys. 2012; 82: e67-75.
Kato I, Ono K, Sakurai Y et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl. Radiat. Isot. 2004; 61: 1069-73.
Kato I, Fujita Y, Maruhashi A et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl. Radiat. Isot. 2009; 67: S37-42.
Wang L-W, Chen Y-W, Ho C-Y et al. Fractionated BNCT for locally recurrent head and neck cancer: experience from a phase I/II clinical trial at Tsing Hua Open-Pool Reactor. Appl. Radiat. Isot. 2014; 88: 23-7.
Wang LW, Liu YH, Chou FI, Jiang SH. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun. 2018; 38: 37.
Koivunoro H, Kankaanranta L, Seppala T, Haapaniemi A, Makitie A, Joensuu H. Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: an analysis of dose response and survival. Radiother. Oncol. 2019; 137: 153-8.
Mishima Y, Ichihashi M, Hatta S et al. First human clinical trial of melanoma neutron capture. Diagnosis and therapy. Strahlenther. Onkol. 1989; 165: 251-4.
Fukuda H, Hiratsuka J, Kobayashi T et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas. Phys. Eng. Sci. Med. 2003; 26: 97-103.
Menéndez PR, Roth B, Pereira MD et al. BNCT for skin melanoma in extremities: updated Argentine clinical results. Appl. Radiat. Isot. 2009; 67: S50-3.
Omori M, Fujiwara S, Shimizu H et al. Boron neutron capture therapy using reactor epithermal neutron beams could effectively control in-transit and lymph node metastases originating from a cutaneous malignant melanoma. J. Dermatol. 2018; 45: e90-1.
Hiratsuka J, Kamitani N, Tanaka R et al. Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT). J. Radiat. Res. 2020; 61: 945-51.
Suzuki M, Sakurai Y, Hagiwara S et al. First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn. J. Clin. Oncol. 2007; 37: 376-81.
Yanagie H, Higashi S, Seguchi K et al. Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion. Appl. Radiat. Isot. 2014; 88: 32-7.
Suzuki M, Endo K, Satoh H et al. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother. Oncol. 2008; 88: 192-5.
Suzuki M, Sakurai Y, Masunaga S et al. Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66: 1584-9.
Suzuki M, Sakurai Y, Masunaga S et al. A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity. Jpn. J. Clin. Oncol. 2007; 37: 245-9.
Farias RO, Bortolussi S, Menendez PR, Gonzalez SJ. Exploring Boron Neutron Capture Therapy for non-small cell lung cancer. Phys. Med. 2014; 30: 888-97.
Wittig A, Malago M, Collette L et al. Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). Int. J. Cancer 2008; 122: 1164-71.
Wittig A, Collette L, Appelman K et al. EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. J. Cell. Mol. Med. 2009; 13: 1653-65.
Wittig A, Collette L, Moss R, Sauerwein WA. Early clinical trial concept for boron neutron capture therapy: a critical assessment of the EORTC trial 11001. Appl. Radiat. Isot. 2009; 67: S59-62.
Sköld K, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Hopewell JW. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br. J. Radiol. 2010; 83: 596-603.
Takahara K, Inamoto T, Minami K et al. The anti-proliferative effect of boron neutron capture therapy in a prostate cancer xenograft model. PLoS One 2015; 10: e0136981.
Gifford I, Vreeland W, Grdanovska S et al. Liposome-based delivery of a boron-containing cholesteryl ester for high-LET particle-induced damage of prostate cancer cells: a boron neutron capture therapy study. Int. J. Radiat. Biol. 2014; 90: 480-5.
Schinazi RF, Hurwitz SJ, Liberman I et al. Tissue disposition of 5-o-carboranyluracil - a novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides Nucleotides Nucleic Acids 2004; 23: 291-306.
Wang S, Blaha C, Santos R et al. Synthesis and initial biological evaluation of boron-containing prostate-specific membrane antigen ligands for treatment of prostate cancer using boron neutron capture therapy. Mol. Pharm. 2019; 16: 3831-41.
Yasui L, Kroc T, Gladden S, Andorf C, Bux S, Hosmane N. Boron neutron capture in prostate cancer cells. Appl. Radiat. Isot. 2012; 70: 6-12.
Barinka C, Byun Y, Dusich CL et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J. Med. Chem. 2008; 51: 7737-43.
Eder M, Schafer M, Bauder-Wust U et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 2012; 23: 688-97.
Hillier SM, Maresca KP, Femia FJ et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69: 6932-40.
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 2016; 13: 226-35.
Yoneyama T, Hatakeyama S, Sutoh Yoneyama M et al. Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy. BMC Cancer 2021; 21: 72.
Hiratsuka J, Fukuda H, Kobayashi T et al. The relative biological effectiveness of 10B-neutron capture therapy for early skin reaction in the hamster. Radiat. Res. 1991; 128: 186-91.